Literature DB >> 22196777

Incidence of cardiac arrhythmias in asymptomatic hereditary hemochromatosis subjects with C282Y homozygosity.

Yukitaka Shizukuda1, Dorothy J Tripodi, Gloria Zalos, Charles D Bolan, Yu-Ying Yau, Susan F Leitman, Myron A Waclawiw, Douglas R Rosing.   

Abstract

It is not well known whether systemic iron overload per se in hereditary hemochromatosis (HH) is associated with cardiac arrhythmias before other signs and symptoms of cardiovascular disease occur. In the present study, we examined the incidence of cardiac arrhythmia in cardiac asymptomatic subjects with HH (New York Heart Association functional class I) and compared it to that in age- and gender-matched normal volunteers. The 42 subjects with HH and the 19 normal control subjects were recruited through the National Heart, Lung, and Blood Institute-sponsored "Heart Study of Hemochromatosis." They completed 48-hour Holter electrocardiography ambulatory monitoring at the baseline evaluation. The subjects with HH were classified as newly diagnosed (group A) and chronically treated (group B) subjects. All subjects with HH had C282Y homozygosity, and the normal volunteers lacked any HFE gene mutations known to cause HH. Although statistically insignificant, the incidence of ventricular and supraventricular ectopy tended to be greater in the combined HH groups than in the controls. Supraventricular ectopy was more frequently noted in group B compared to in the controls (ectopy rate per hour 11.1 ± 29.9 vs 1.5 ± 3.5, p < 0.05, using the Kruskal-Wallis test). No examples of heart block, other than first-degree atrioventricular node block, were seen in any of the subjects. The incidence of cardiac arrhythmias was not significantly reduced after 6 months of intensive iron removal therapy in the group A subjects. No life-threatening arrhythmias were observed in our subjects with HH. In conclusion, our data suggest that the incidence of cardiac arrhythmias is, at most, marginally increased in asymptomatic subjects with HH. A larger clinical study is warranted to further clarify our observation. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22196777      PMCID: PMC3294140          DOI: 10.1016/j.amjcard.2011.11.011

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  18 in total

1.  Idiopathic hemochromatosis in a young man presenting with palpitations.

Authors:  C A Vargas; H M Méndez; C E Rubio; E A Torres
Journal:  Bol Asoc Med P R       Date:  1991-01

2.  Hemochromatosis with auricular fibrillation; a case report.

Authors:  W R GRIFFIN; H G NELSON; J R SEAL
Journal:  Am Heart J       Date:  1950-06       Impact factor: 4.749

3.  Exercise capacity of cardiac asymptomatic hereditary hemochromatosis subjects.

Authors:  Yukitaka Shizukuda; Charles D Bolan; Dorothy J Tripodi; Yu-Ying Yau; Kevin P Smith; Ross Arena; Myron A Waclawiw; Susan F Leitman; Douglas R Rosing
Journal:  Med Sci Sports Exerc       Date:  2007-01       Impact factor: 5.411

4.  Atrioventricular block in familial hemochromatosis treated by permanent synchronous pacemaker.

Authors:  W S Aronow; L Meister; J R Kent
Journal:  Arch Intern Med       Date:  1969-04

5.  Sustained ventricular tachycardia in cardiac hemochromatosis treated with amiodarone.

Authors:  S Yalçinkaya; S D Kumbasar; E Semiz; Z Tosun; N Paksoy
Journal:  J Electrocardiol       Date:  1997-04       Impact factor: 1.438

6.  Value of signal-averaged electrocardiography, radionuclide ventriculography, Holter monitoring and clinical variables for prediction of arrhythmic events in survivors of acute myocardial infarction in the thrombolytic era.

Authors:  B M McClements; A A Adgey
Journal:  J Am Coll Cardiol       Date:  1993-05       Impact factor: 24.094

7.  Syncope and inducible ventricular fibrillation in a woman with hemochromatosis.

Authors:  J S Strobel; A R Fuisz; A E Epstein; V J Plumb
Journal:  J Interv Card Electrophysiol       Date:  1999-10       Impact factor: 1.900

Review 8.  The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation.

Authors:  Panagiotis Korantzopoulos; Theofilos M Kolettis; Dimitrios Galaris; John A Goudevenos
Journal:  Int J Cardiol       Date:  2006-06-09       Impact factor: 4.164

9.  Left ventricular systolic function during stress echocardiography exercise in subjects with asymptomatic hereditary hemochromatosis.

Authors:  Yukitaka Shizukuda; Charles D Bolan; Dorothy J Tripodi; Yu-Ying Yau; Kevin P Smith; Vandana Sachdev; Charles W Birdsall; Stanislav Sidenko; Myron A Waclawiw; Susan F Leitman; Douglas R Rosing
Journal:  Am J Cardiol       Date:  2006-07-07       Impact factor: 2.778

Review 10.  Factors predisposing to the development of atrial fibrillation.

Authors:  S Lévy
Journal:  Pacing Clin Electrophysiol       Date:  1997-10       Impact factor: 1.976

View more
  4 in total

1.  Iron Overload or Oxidative Stress? Insight into a Mechanism of Early Cardiac Manifestations of Asymptomatic Hereditary Hemochromatosis Subjects with C282Y Homozygosity.

Authors:  Yukitaka Shizukuda; Dorothy J Tripodi; Douglas R Rosing
Journal:  J Cardiovasc Transl Res       Date:  2016-06-08       Impact factor: 4.132

Review 2.  Advancement of echocardiography for surveillance of iron overload cardiomyopathy: comparison to cardiac magnetic resonance imaging.

Authors:  M Jason Zimmerman; Douglas R Rosing; Yukitaka Shizukuda
Journal:  J Echocardiogr       Date:  2021-03-26

Review 3.  Iron overload and arrhythmias: Influence of confounding factors.

Authors:  Yukitaka Shizukuda; Douglas R Rosing
Journal:  J Arrhythm       Date:  2019-06-20

Review 4.  Hereditary Hemochromatosis: A Cardiac Perspective.

Authors:  Pranay K Joshi; Saawan C Patel; Devarashetty Shreya; Diana I Zamora; Gautami S Patel; Idan Grossmann; Kevin Rodriguez; Mridul Soni; Ibrahim Sange
Journal:  Cureus       Date:  2021-11-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.